Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
The Ras Gene02:38

The Ras Gene

6.9K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

18.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.2K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

5.1K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody.

Journal for immunotherapy of cancer·2026
Same author

IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancers.

Cancer discovery·2026
Same author

Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma.

Nature·2026
Same author

Spatial transcriptomics reveals the molecular signatures of prodromal and advanced α-synucleinopathy.

iScience·2026
Same author

MIF-CD74 signaling drives immune modulation in medulloblastoma.

Neuro-oncology·2026
Same author

Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout.

Cancers·2025
Same journal

Mutation detection in women diagnosed with endometrial cancer: a next-generation sequencing analysis.

Molecular & cellular oncology·2026
Same journal

Evolutionary perspectives on endometrial cancer: antagonistic pleiotropy.

Molecular & cellular oncology·2026
Same journal

mRNA vaccines in oncology: personalized cancer immunization and neoantigen targeting.

Molecular & cellular oncology·2026
Same journal

Exploration of the diagnostic and therapeutic potential of the nucleocytoplasmic shuttling protein TMUB1 by inducing G0/G1 cell cycle arrest in ovarian cancer.

Molecular & cellular oncology·2026
Same journal

The LNK adaptor protein: a dual regulator of proliferation and migration in solid tumors.

Molecular & cellular oncology·2026
Same journal

Lactylation-related genes signature panel in hepatocellular carcinoma reveals the prognostic and therapeutic optimization.

Molecular & cellular oncology·2026
See all related articles

Related Experiment Video

Updated: Dec 29, 2025

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

15.2K

RAS-driven oncogenesis is supported by downstream antioxidant programs.

Jonathan K M Lim1, Gabriel Leprivier1, Poul H Sorensen2,3

  • 1Department of Neuropathology, Heinrich Heine University, Düsseldorf, Germany.

Molecular & Cellular Oncology
|January 30, 2020
PubMed
Summary
This summary is machine-generated.

Oncogenic RAS transformation upregulates the cystine/glutamate transporter SLC7A11 (XCT). This enhances glutathione production, helping RAS-transformed cells manage oxidative stress during tumorigenesis.

More Related Videos

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.8K

Related Experiment Videos

Last Updated: Dec 29, 2025

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

15.2K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Oncogenic RAS proteins are key drivers of cell transformation and tumor development.
  • Cancer cells often exhibit increased oxidative stress, necessitating adaptive mechanisms for survival.
  • The cystine/glutamate transporter SLC7A11 (XCT) plays a role in cellular redox balance.

Purpose of the Study:

  • To investigate the role of SLC7A11 (XCT) in RAS-mediated cell transformation and tumorigenesis.
  • To elucidate the mechanism by which RAS influences antioxidant pathways.
  • To determine if SLC7A11 (XCT) expression is a target for RAS-driven cancer adaptation.

Main Methods:

  • Analysis of gene expression in RAS-transformed cells.
  • Assessment of glutathione biosynthesis pathways.
  • Evaluation of oxidative stress markers in cancer cells.
  • In vivo studies to confirm the role of SLC7A11 (XCT) in tumor growth.

Main Results:

  • Transcriptional induction of SLC7A11 (XCT) was observed in oncogenic RAS-transformed cells.
  • Increased SLC7A11 (XCT) expression correlated with enhanced glutathione biosynthesis.
  • RAS-transformed cells showed reduced oxidative stress, attributed to elevated glutathione levels.
  • Inhibition of SLC7A11 (XCT) impaired tumor growth in vivo.

Conclusions:

  • Oncogenic RAS promotes tumorigenesis by upregulating SLC7A11 (XCT), a critical antioxidant.
  • SLC7A11 (XCT)-mediated glutathione synthesis is essential for RAS-transformed cells to cope with oxidative stress.
  • Targeting SLC7A11 (XCT) represents a potential therapeutic strategy against RAS-driven cancers.